Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

I think some of this has to do with Inari’s more limited product portfolio and the fact that mechanical thrombectomy for VTE is still something of a “missionary” sale with many physicians.

On Tuesday, Canaccord Genuity adjusted its stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ: NARI) stock, downgrading it from Buy to Hold, while increasing the price target to $80.00, up from the ...

Stryker's definitive agreement to purchase Inari Medical aims to enhance its product offerings by adding Inari's mechanical thrombectomy devices to its neurovascular portfolio. The integration is ...

Inari makes mechanical thrombectomy solutions designed to treat peripheral vascular diseases. The Irvine, Calif.-based company has about 1,400 employees and earned about $603 million in revenue ...

Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Inari is poised to enhance Stryker's footprint in the peripheral vascular sector, particularly in the venous thromboembolism (VTE) market. The company’s portfolio of mechanical thrombectomy ...

The deal, announced after hours on Monday, propelled Inari (NASDAQ:NARI ... as PEN is the other main US venous (VTE) & arterial thrombectomy player competing against NARI,” Truist analyst ...

Stryker acquires Inari Medical for $80/share, valuing the deal at $4.9 billion, expanding its venous thromboembolism portfolio. Mechanical thrombectomy for VTE is a $6 billion US market ...